BUSINESS● LOW1d ago · Oct 20, 2026, 7:33 PM
Protein degrader drug developer Lycia seeks $228M in U.S. IPO
Seeking Alpha Tech · north america
Lycia, a company developing protein degrader drugs, is seeking to raise $228 million through an initial public offering in the U.S. This marks a significant financial step for the biotechnology firm.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS13m agoNvidia CEO Jensen Huang says neocloud demand is 'off the charts' but capital is scarceCNBCBUSINESS13m agoHoneywell International misses Q3 revenue estimates, lifts 2026 revenue and earnings guidanceSeeking Alpha Tech